<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7295552\results\search\disease\results.xml">
  <result pre="medium, provided the original work is properly cited. Abstract Coronavirus" exact="disease" post="2019 is caused by severe acute respiratory syndrome coronavirus"/>
  <result pre="properly cited. Abstract Coronavirus disease 2019 is caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), and this infectious disease"/>
  <result pre="cited. Abstract Coronavirus disease 2019 is caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), and this infectious disease is"/>
  <result pre="Abstract Coronavirus disease 2019 is caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), and this infectious disease is termed"/>
  <result pre="by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and this" exact="infectious disease" post="is termed COVID-19 in short. On a global scale,"/>
  <result pre="severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and this infectious" exact="disease" post="is termed COVID-19 in short. On a global scale,"/>
  <result pre="part of supportive care in complicated cases of COVID-19. Coronavirus" exact="disease" post="2019 SARS-CoV-2 Pharmacological treatment Medical management HIV Transplant ESKD"/>
  <result pre="SARS-CoV-2 Pharmacological treatment Medical management HIV Transplant ESKD Introduction Coronavirus" exact="disease" post="2019 is caused by severe acute respiratory syndrome coronavirus"/>
  <result pre="Transplant ESKD Introduction Coronavirus disease 2019 is caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), and this infectious disease"/>
  <result pre="ESKD Introduction Coronavirus disease 2019 is caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), and this infectious disease is"/>
  <result pre="Introduction Coronavirus disease 2019 is caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), and this infectious disease is termed"/>
  <result pre="by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and this" exact="infectious disease" post="is termed COVID-19 in short. The disease was first"/>
  <result pre="severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and this infectious" exact="disease" post="is termed COVID-19 in short. The disease was first"/>
  <result pre="and this infectious disease is termed COVID-19 in short. The" exact="disease" post="was first officially reported in December 2019 in Wuhan,"/>
  <result pre="COVID-19 pandemic. As of June 1, 2020, the Centers for" exact="Disease" post="Control and Prevention (CDC) reported that a total of"/>
  <result pre="Centers for Disease Control and Prevention (CDC) reported that a" exact="total" post="of 1,787,680 people were COVID-19 positive in the USA,"/>
  <result pre="this novel coronavirus can range from being asymptomatic or minimal" exact="respiratory" post="symptoms to febrile illness, as well as severe respiratory"/>
  <result pre="minimal respiratory symptoms to febrile illness, as well as severe" exact="respiratory" post="failure needing ventilator support. Despite reported observational data about"/>
  <result pre="as part of supportive care in complicated cases of COVID-19." exact="General" post="Issues Around Medical Management of COVID-19 Use of non-steroidal"/>
  <result pre="of NSAID use early during COVID-19 and progression to severe" exact="disease" post="in young adults [3]. However, there has been no"/>
  <result pre="conditions, unless there are clinical rationale to stop them (e.g.," exact="acute" post="renal injury, gastrointestinal (GI) bleeding). Role of glucocorticoids In"/>
  <result pre="increased risk for mortality in patients with influenza and delayed" exact="viral" post="clearance in patients with Middle East respiratory syndrome coronavirus"/>
  <result pre="influenza and delayed viral clearance in patients with Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) infection. Although they were widely used"/>
  <result pre="and delayed viral clearance in patients with Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) infection. Although they were widely used in"/>
  <result pre="Although they were widely used in the management of severe" exact="acute" post="respiratory syndrome (SARS), there was no good evidence for"/>
  <result pre="they were widely used in the management of severe acute" exact="respiratory" post="syndrome (SARS), there was no good evidence for benefit,"/>
  <result pre="were widely used in the management of severe acute respiratory" exact="syndrome" post="(SARS), there was no good evidence for benefit, and"/>
  <result pre="long-term harm [5]. Therefore, CDC recommended against the use of" exact="systemic" post="glucocorticoids in patients with COVID-19, unless there are other"/>
  <result pre="patients with COVID-19, unless there are other indications such as" exact="asthma" post="or chronic obstructive lung disease exacerbation, refractory septic shock,"/>
  <result pre="with COVID-19, unless there are other indications such as asthma" exact="or chronic" post="obstructive lung disease exacerbation, refractory septic shock, and adrenal"/>
  <result pre="COVID-19, unless there are other indications such as asthma or" exact="chronic" post="obstructive lung disease exacerbation, refractory septic shock, and adrenal"/>
  <result pre="unless there are other indications such as asthma or chronic" exact="obstructive lung disease" post="exacerbation, refractory septic shock, and adrenal insufficiency. However, their"/>
  <result pre="there are other indications such as asthma or chronic obstructive" exact="lung disease" post="exacerbation, refractory septic shock, and adrenal insufficiency. However, their"/>
  <result pre="are other indications such as asthma or chronic obstructive lung" exact="disease" post="exacerbation, refractory septic shock, and adrenal insufficiency. However, their"/>
  <result pre="such as asthma or chronic obstructive lung disease exacerbation, refractory" exact="septic shock," post="and adrenal insufficiency. However, their administration in critically ill"/>
  <result pre="or chronic obstructive lung disease exacerbation, refractory septic shock, and" exact="adrenal insufficiency." post="However, their administration in critically ill patients with COVID-19-related"/>
  <result pre="insufficiency. However, their administration in critically ill patients with COVID-19-related" exact="adult" post="respiratory distress syndrome (ARDS) is controversial. Based on data"/>
  <result pre="However, their administration in critically ill patients with COVID-19-related adult" exact="respiratory" post="distress syndrome (ARDS) is controversial. Based on data suggesting"/>
  <result pre="administration in critically ill patients with COVID-19-related adult respiratory distress" exact="syndrome" post="(ARDS) is controversial. Based on data suggesting the potential"/>
  <result pre="14 days, doses should be low, and courses should be" exact="short" post="(e.g., intravenous (IV) dexamethasone 20 mg once daily for"/>
  <result pre="prophylaxis Patients with COVID-19 may carry an increased risk for" exact="systemic" post="thrombosis. This is suggested by published case reports of"/>
  <result pre="systemic thrombosis. This is suggested by published case reports of" exact="pulmonary embolism" post="in patients with COVID-19, and several cohorts reported to"/>
  <result pre="existing comorbidities. Additionally, markers of dysregulated coagulation and evidence of" exact="disseminated intravascular coagulation" post="(DIC) have been seen to be associated with more"/>
  <result pre="(DIC) have been seen to be associated with more severe" exact="disease" post="and death in patients with COVID-19 [7]. However, the"/>
  <result pre="remains unknown. As with all hospitalized patients, pharmacologic prophylaxis of" exact="venous thromboembolism" post="is recommended even in COVID-19 patients, typically using low-molecular-weight"/>
  <result pre="low-molecular-weight heparin, unless there are clinical contraindications such as active" exact="bleeding" post="or severe thrombocytopenia. Use of nebulized medications Inhaled medications"/>
  <result pre="therapy must be used, patients should be in an airborne" exact="infection" post="isolation room (preferably negative pressure room), and any healthcare"/>
  <result pre="transmission of the virus. Empiric use of antibiotics for superimposed" exact="bacterial pneumonia" post="Clinical features of COVID-19 are challenging to distinguish from"/>
  <result pre="of the virus. Empiric use of antibiotics for superimposed bacterial" exact="pneumonia" post="Clinical features of COVID-19 are challenging to distinguish from"/>
  <result pre="pneumonia Clinical features of COVID-19 are challenging to distinguish from" exact="bacterial pneumonia." post="Empiric treatment for bacterial pneumonia may also be reasonable"/>
  <result pre="are challenging to distinguish from bacterial pneumonia. Empiric treatment for" exact="bacterial pneumonia" post="may also be reasonable in patients with documented COVID-19"/>
  <result pre="challenging to distinguish from bacterial pneumonia. Empiric treatment for bacterial" exact="pneumonia" post="may also be reasonable in patients with documented COVID-19"/>
  <result pre="A low procalcitonin level usually is helpful to suggest against" exact="bacterial pneumonia;" post="however, elevated procalcitonin has been described in the late"/>
  <result pre="the late stage of COVID-19 and does not necessarily indicate" exact="bacterial pneumonia" post="[8]. Continuation of Chronic Medical Therapy: Some Special Circumstances"/>
  <result pre="late stage of COVID-19 and does not necessarily indicate bacterial" exact="pneumonia" post="[8]. Continuation of Chronic Medical Therapy: Some Special Circumstances"/>
  <result pre="and does not necessarily indicate bacterial pneumonia [8]. Continuation of" exact="Chronic" post="Medical Therapy: Some Special Circumstances Angiotensin-converting enzyme inhibitors (ACEIs)"/>
  <result pre="but there is no conclusive evidence to support this hypothesis." exact="Multiple" post="experts and guidelines recommended that patients who are already"/>
  <result pre="if there is no other reason for discontinuation (e.g., hypotension," exact="acute" post="kidney injury (AKI)) [10]. Statins Concern has been raised"/>
  <result pre="there is no other reason for discontinuation (e.g., hypotension, acute" exact="kidney injury" post="(AKI)) [10]. Statins Concern has been raised regarding potential"/>
  <result pre="other hand, statins are known inhibitors of the myeloid differentiation" exact="primary" post="response 88 (MYD88) pathway, which results in marked inflammation,"/>
  <result pre="been reported to stabilize MYD88 levels in the setting of" exact="external" post="stress in vitro and animal studies. Dysregulation of MYD88"/>
  <result pre="immunosuppressive agents has been associated with increased risk for severe" exact="disease" post="with respiratory viruses. However, no evidence routinely discontinuing treatment"/>
  <result pre="has been associated with increased risk for severe disease with" exact="respiratory" post="viruses. However, no evidence routinely discontinuing treatment is of"/>
  <result pre="support the approach of continuing immunomodulatory therapy in patients without" exact="infection" post="[12]. Symptomatic management Fever is the most common symptom"/>
  <result pre="continuing immunomodulatory therapy in patients without infection [12]. Symptomatic management" exact="Fever" post="is the most common symptom and was noted in"/>
  <result pre="NSAID use and worsening of COVID-19 severity [3]. Aspirin causes" exact="Reye syndrome," post="and should be avoided in children. Cough (often dry"/>
  <result pre="risk of aerosolization and the spread of the virus [14]." exact="Hypotension" post="and shock are potential complications of COVID-19. Vasopressors are"/>
  <result pre="and has been discussed earlier in this article. Management of" exact="respiratory" post="failure Viral infection causes inflammatory cytokine release and thereby"/>
  <result pre="been discussed earlier in this article. Management of respiratory failure" exact="Viral" post="infection causes inflammatory cytokine release and thereby edema in"/>
  <result pre="discussed earlier in this article. Management of respiratory failure Viral" exact="infection" post="causes inflammatory cytokine release and thereby edema in various"/>
  <result pre="infection causes inflammatory cytokine release and thereby edema in various" exact="vascular" post="beds, usually subpleural in the early stages and alveolar"/>
  <result pre="the early stages and alveolar edema in later stages [16]." exact="Vascular" post="endothelial damage in COVID-19 disrupts pulmonary vascular autoregulation in"/>
  <result pre="in later stages [16]. Vascular endothelial damage in COVID-19 disrupts" exact="pulmonary" post="vascular autoregulation in response to hypoxia and contributes to"/>
  <result pre="later stages [16]. Vascular endothelial damage in COVID-19 disrupts pulmonary" exact="vascular" post="autoregulation in response to hypoxia and contributes to ventilation-perfusion"/>
  <result pre="damage in COVID-19 disrupts pulmonary vascular autoregulation in response to" exact="hypoxia" post="and contributes to ventilation-perfusion (VQ) mismatch [17]. Moreover, inflammation"/>
  <result pre="lining, as well as decreased fluid clearance, leads to alveolar" exact="collapse" post="and edema. The respiratory mechanics, pathology, and clinical features"/>
  <result pre="decreased fluid clearance, leads to alveolar collapse and edema. The" exact="respiratory" post="mechanics, pathology, and clinical features change with disease progression"/>
  <result pre="edema. The respiratory mechanics, pathology, and clinical features change with" exact="disease" post="progression in COVID-19. With the worsening of the disease"/>
  <result pre="with disease progression in COVID-19. With the worsening of the" exact="disease" post="process, alveolar edema leads to increased right heart pressure,"/>
  <result pre="of the disease process, alveolar edema leads to increased right" exact="heart" post="pressure, which in turn causes more tissue hypoxia and"/>
  <result pre="increased right heart pressure, which in turn causes more tissue" exact="hypoxia" post="and multi-organ failure [18]. Gattinoni et al conceptualized two"/>
  <result pre="stages/ARDS) at the ends of the clinical spectrum with possible" exact="intermediate" post="cases with overlapping features [16, 17]. The â€œLâ€� type"/>
  <result pre="much scope for recruitability [16]. These patients have mild dyspnea," exact="limited" post="ground glass infiltrates on computed tomography (CT) scans, and"/>
  <result pre="distress. The â€œHâ€� type is found later in the COVID-19" exact="disease" post="process with more resemblance to ARDS. It is the"/>
  <result pre="high recruitability [16]. These explain the resemblance to ARDS (non-cardiogenic" exact="pulmonary" post="edema, shunting, and decreased lung size for gas exchange)."/>
  <result pre="and decreased lung size for gas exchange). These patients are" exact="symptomatic" post="and with extensive infiltrates on CT suggestive of alveolar"/>
  <result pre="up on the ventilator support device. Based on these concepts," exact="respiratory" post="support in COVID-19 should focus on optimizing oxygenation, reducing"/>
  <result pre="respiratory support in COVID-19 should focus on optimizing oxygenation, reducing" exact="pulmonary" post="and vascular stress, preventing edema and lung injury, and"/>
  <result pre="in COVID-19 should focus on optimizing oxygenation, reducing pulmonary and" exact="vascular" post="stress, preventing edema and lung injury, and recruitment of"/>
  <result pre="lung injury, and recruitment of functional lung units [17]. For" exact="acute" post="hypoxemic respiratory failure, the recommended goal is to provide"/>
  <result pre="and recruitment of functional lung units [17]. For acute hypoxemic" exact="respiratory" post="failure, the recommended goal is to provide supplemental oxygen"/>
  <result pre="ventilation [19]. In general, indications for intubation include clinically worsening" exact="respiratory" post="distress, rapidly progressive disease, SpO2 less than 90% despite"/>
  <result pre="progressive disease, SpO2 less than 90% despite maximal supplemental oxygen," exact="acidosis" post="with pH less than 7.3, and partial pressure of"/>
  <result pre="maximal supplemental oxygen, acidosis with pH less than 7.3, and" exact="partial" post="pressure of carbon dioxide (PaCO2) more than 50 mm"/>
  <result pre="tidal volume 4 - 8 mL/kg ideal predicted body weight;" exact="respiratory" post="rate 25 - 30 breaths/min; positive end expiratory pressure"/>
  <result pre="less than 30 cm H2O. The L type patients tolerate" exact="lower" post="PEEP (&amp;lt; 10 cm H2O) and higher tidal volume"/>
  <result pre="lung compliance, need higher PEEP (&amp;lt; 15 cm H2O) and" exact="lower" post="tidal volumes (5 - 7 mL/kg) [17]. Prone positioning"/>
  <result pre="to prone positioning include shock, active bleeding, recent tracheal surgery," exact="multiple fractures," post="and spine instability [15]. Recruitment maneuvers, high PEEP strategies,"/>
  <result pre="include shock, active bleeding, recent tracheal surgery, multiple fractures, and" exact="spine" post="instability [15]. Recruitment maneuvers, high PEEP strategies, and trial"/>
  <result pre="[15]. Recruitment maneuvers, high PEEP strategies, and trial of inhaled" exact="pulmonary" post="vasodilators are probable options for patients that failed prone"/>
  <result pre="oxygenation (ECMO) is used in patients with refractory cardiac and" exact="respiratory" post="failure in whom usually the venous blood is removed"/>
  <result pre="unclear but may be used in patients with refractory hypoxemic" exact="respiratory" post="failure. Venovenous ECMO has been used as a last"/>
  <result pre="high and &amp;gt; 90% in one analysis [21]. Pharmacological Therapy" exact="Multiple" post="pharmacotherapies have been tried on an experimental basis on"/>
  <result pre="mechanism of macrolides is scarce and was hypothesized to inhibit" exact="respiratory" post="syncytial virus through the reduced expression of fusion protein"/>
  <result pre="and the inhibition of subsequent Rho-kinase activation in human airway" exact="epithelial" post="cells [22]. Azithromycin was shown to inhibit replication in"/>
  <result pre="tolerated and has been used for ages in patients with" exact="systemic" post="lupus erythematosus (SLE) and malaria. However, both agents can"/>
  <result pre="and has been used for ages in patients with systemic" exact="lupus erythematosus" post="(SLE) and malaria. However, both agents can cause serious"/>
  <result pre="effects, QTc prolongation. Azithromycin is a commonly used macrolide for" exact="respiratory" post="bacterial infections. Gautret et al concluded that combination therapy"/>
  <result pre="QTc prolongation. Azithromycin is a commonly used macrolide for respiratory" exact="bacterial infections." post="Gautret et al concluded that combination therapy with azithromycin"/>
  <result pre="for two doses, then 400 mg daily orally for a" exact="total" post="of 5 days. Chloroquine dose suggested by FDA is"/>
  <result pre="C-adenosine nucleoside triphosphate analog, thereby interfering with the action of" exact="viral" post="RNA-dependent RNA polymerase. Pros and cons The agent was"/>
  <result pre="less than 30 mL/min [29]. Favipiravir MOA Favipiravir inhibits influenza" exact="viral" post="replications by targeting RNA polymerase, and this mechanism is"/>
  <result pre="generic version of brand Avigan used for treating novel influenza" exact="infections" post="in Japan. Notable side effects include decreased neutrophil count,"/>
  <result pre="day as maintenance dose [29]. Interleukin (IL)-6 pathway inhibitor MOA" exact="Elevated" post="levels of the inflammatory marker, including IL-6, were found"/>
  <result pre="Lopinavir/ritonavir MOA The lopinavir component binds to the site of" exact="viral" post="protease activity and inhibits the cleavage of viral Gag-Pol"/>
  <result pre="site of viral protease activity and inhibits the cleavage of" exact="viral" post="Gag-Pol polyprotein precursors into individual functional proteins required for"/>
  <result pre="viral Gag-Pol polyprotein precursors into individual functional proteins required for" exact="infectious" post="human immunodeficiency virus (HIV). This results in the formation"/>
  <result pre="polyprotein precursors into individual functional proteins required for infectious human" exact="immunodeficiency" post="virus (HIV). This results in the formation of immature,"/>
  <result pre="virus (HIV). This results in the formation of immature, noninfectious" exact="viral" post="particles. The ritonavir component inhibits the cytochrome P450 3A"/>
  <result pre="has not shown any effective benefit. No significant differences in" exact="viral" post="clearance or 28-day mortality rates were observed in 199"/>
  <result pre="in patients receiving lopinavir therapy are asthenia, diarrhea, and nausea." exact="Elevated" post="total bilirubin, hepatic enzyme levels, and triglycerides have also"/>
  <result pre="patients receiving lopinavir therapy are asthenia, diarrhea, and nausea. Elevated" exact="total" post="bilirubin, hepatic enzyme levels, and triglycerides have also been"/>
  <result pre="antiviral effects of this H2RA were demonstrated in patients with" exact="herpes zoster" post="infection, herpes simplex virus (HSV), and human papillomavirus (HPV)"/>
  <result pre="effects of this H2RA were demonstrated in patients with herpes" exact="zoster" post="infection, herpes simplex virus (HSV), and human papillomavirus (HPV)"/>
  <result pre="this H2RA were demonstrated in patients with herpes zoster infection," exact="herpes" post="simplex virus (HSV), and human papillomavirus (HPV) [38-40]. It"/>
  <result pre="increased immunogenicity when given as an adjuvant along with HBV" exact="viral" post="vaccines [41]. It also decreased HIV replication in vitro"/>
  <result pre="helps against COVID-19. This thought originated from Michael Callahan, an" exact="infectious disease" post="doctor at Massachusetts General Hospital. He observed that many"/>
  <result pre="against COVID-19. This thought originated from Michael Callahan, an infectious" exact="disease" post="doctor at Massachusetts General Hospital. He observed that many"/>
  <result pre="originated from Michael Callahan, an infectious disease doctor at Massachusetts" exact="General" post="Hospital. He observed that many of the COVID-19 survivors"/>
  <result pre="Hospital. He observed that many of the COVID-19 survivors had" exact="chronic" post="heartburn and took famotidine rather than omeprazole, which is"/>
  <result pre="statistically significant. Proposed dose for COVID-19 Standard dose to treat" exact="gastroesophageal reflux disease." post="Interferon (IFN) beta MOA IFN-beta is a subtype of"/>
  <result pre="significant. Proposed dose for COVID-19 Standard dose to treat gastroesophageal" exact="reflux" post="disease. Interferon (IFN) beta MOA IFN-beta is a subtype"/>
  <result pre="disease. Interferon (IFN) beta MOA IFN-beta is a subtype of" exact="type I" post="IFN secreted by many cell types, mostly by plasmacytoid"/>
  <result pre="cell types, mostly by plasmacytoid dendritic cells upon recognition of" exact="viral" post="components by pattern recognition receptors (PRR). IFN-stimulated genes (ISG)"/>
  <result pre="(ISG) are involved in inflammation and immunomodulation. ISGs interfere with" exact="viral" post="replication and viral spread through different pathways like cytokine"/>
  <result pre="in inflammation and immunomodulation. ISGs interfere with viral replication and" exact="viral" post="spread through different pathways like cytokine secretion or slowdown"/>
  <result pre="IFN-beta as a potential treatment option against SARS-CoV-2 [44, 45]." exact="Type I" post="(IFN-alpha and beta) IFNs were efficient in vitro and"/>
  <result pre="also in specific animal models but failed to control the" exact="disease" post="in humans [44]. It was hypothesized that SARS-CoV-2 induces"/>
  <result pre="the plasma collected from donors who have successfully survived an" exact="infectious disease" post="by generating antibodies. CP has been in use for"/>
  <result pre="plasma collected from donors who have successfully survived an infectious" exact="disease" post="by generating antibodies. CP has been in use for"/>
  <result pre="in 2003, H1N1 influenza pandemic (H1N1) in 2009 - 2010," exact="avian influenza" post="A (H5N1), Ebola and MERS-CoV epidemic in 2012 [47-52]."/>
  <result pre="MOA The antibodies in the CP could potentially limit the" exact="viral" post="replication, can mediate cellular toxicity and/or phagocytosis, and the"/>
  <result pre="offer the only short-term strategy to confer immediate immunity to" exact="infection" post="susceptible patients [53]. In the absence of an effective"/>
  <result pre="confer immediate immunity to infection susceptible patients [53]. In the" exact="absence of" post="an effective specific treatment for COVID-19, clinicians across the"/>
  <result pre="the infection, of whom, 80 patients received CP had a" exact="lower" post="mortality rate (12.5%) compared to overall SARS-related mortality. The"/>
  <result pre="most effective if given prophylactically or used early in the" exact="disease" post="course. Proposed dose for COVID-19 Even though there is"/>
  <result pre="be used in patients with severe or immediately life-threatening COVID-19" exact="infections" post="starting March 24, 2020. The treatment with CP is"/>
  <result pre="enough antibody levels in the plasma and negative for possible" exact="infections" post="such as HIV, hepatitis C, etc. The donor and"/>
  <result pre="the plasma and negative for possible infections such as HIV," exact="hepatitis C," post="etc. The donor and the recipient should have compatible"/>
  <result pre="Though been in use for over 100 years for various" exact="infectious diseases," post="there is a severe lack of cooperative global efforts"/>
  <result pre="and emerging epidemics and pandemics. More than 4.5 million global" exact="infections" post="and growing, COVID-19 provides an opportunity to perform large-scale"/>
  <result pre="to perform large-scale rigorous clinical studies on CP against the" exact="viral" post="agents to establish clinical efficacy. This pandemic could provide"/>
  <result pre="efficacy. This pandemic could provide a strategic pathway for future" exact="viral" post="pandemic management with CP. Plasma adsorption and exchange Emerging"/>
  <result pre="may be beneficial [30, 59]. In the case of fulminant" exact="systemic" post="infection, patients may develop sepsis, ARDS, and multi-organ failure,"/>
  <result pre="effective antiviral therapy is being sought; however, treatment of the" exact="systemic" post="response to this viral infection is likely to be"/>
  <result pre="being sought; however, treatment of the systemic response to this" exact="viral infection" post="is likely to be equally or more important. Overzealous"/>
  <result pre="sought; however, treatment of the systemic response to this viral" exact="infection" post="is likely to be equally or more important. Overzealous"/>
  <result pre="to be equally or more important. Overzealous host response to" exact="infection" post="has been well described and involves a complex interaction"/>
  <result pre="critically ill COVID-19 patients has a strong correlation with the" exact="disease" post="severities. Monitoring inflammation and antibodies is significant, especially in"/>
  <result pre="performed with the close guidance of specialists, and risks of" exact="infection" post="or bleeding are minimized. So far, randomized trial data"/>
  <result pre="the close guidance of specialists, and risks of infection or" exact="bleeding" post="are minimized. So far, randomized trial data are not"/>
  <result pre="have been reports that patients living with HIV and COVID-19" exact="pneumonia" post="receiving ART may have moderate symptoms and faster improvement"/>
  <result pre="moderate symptoms and faster improvement than the general population and" exact="atypical" post="CT imaging features from the conventional population. The preliminary"/>
  <result pre="and COVID-19 COVID-19 has raised various concerns among patients on" exact="chronic" post="immunosuppressive therapy because the immune response to the virus"/>
  <result pre="risk of any infection. However, it has been described that" exact="uncontrolled" post="disease activity in patients with rheumatoid arthritis and SLE"/>
  <result pre="of any infection. However, it has been described that uncontrolled" exact="disease" post="activity in patients with rheumatoid arthritis and SLE puts"/>
  <result pre="has been described that uncontrolled disease activity in patients with" exact="rheumatoid arthritis" post="and SLE puts them at a significantly higher risk"/>
  <result pre="been described that uncontrolled disease activity in patients with rheumatoid" exact="arthritis" post="and SLE puts them at a significantly higher risk"/>
  <result pre="SLE puts them at a significantly higher risk for outpatient" exact="infections" post="and hospitalization [69, 70]. It is of utmost importance"/>
  <result pre="to optimize patient medication adherence to prevent any discontinuation of" exact="chronic" post="treatment, which may lead to disease flare and increased"/>
  <result pre="prevent any discontinuation of chronic treatment, which may lead to" exact="disease" post="flare and increased risk of infection [71]. Some disease-modifying"/>
  <result pre="which may lead to disease flare and increased risk of" exact="infection" post="[71]. Some disease-modifying drugs which are commonly used to"/>
  <result pre="[71]. Some disease-modifying drugs which are commonly used to treat" exact="rheumatic" post="diseases, such as biologics targeting IL-6 (tocilizumab, sarilumab) and"/>
  <result pre="for COVID-19, especially in patients with cytokine storm and reactive" exact="hemophagocytic lymphohistiocytosis." post="However, conclusive evidence is lacking to guide treatment decisions"/>
  <result pre="course of COVID-19 in a series of 320 patients with" exact="chronic" post="arthritis treated with targeted immunosuppressive therapies. This included patients"/>
  <result pre="of COVID-19 in a series of 320 patients with chronic" exact="arthritis" post="treated with targeted immunosuppressive therapies. This included patients with"/>
  <result pre="arthritis treated with targeted immunosuppressive therapies. This included patients with" exact="rheumatoid arthritis" post="and spondyloarthritis, treated with biological derived disease-modifying anti-rheumatic drugs"/>
  <result pre="treated with targeted immunosuppressive therapies. This included patients with rheumatoid" exact="arthritis" post="and spondyloarthritis, treated with biological derived disease-modifying anti-rheumatic drugs"/>
  <result pre="anti-rheumatic drugs (bDMARDs), targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs) or" exact="tumor" post="necrosis factor inhibitors. bDMARDs or tsDMARDs were held in"/>
  <result pre="inhibitors. bDMARDs or tsDMARDs were held in eight patients with" exact="symptomatic" post="COVID-19 with fever and shortness of breath. The study"/>
  <result pre="of breath. The study reported no significant relapses of the" exact="rheumatic" post="disease, no mortality from COVID-19. It is suggested that"/>
  <result pre="no mortality from COVID-19. It is suggested that patients with" exact="chronic" post="arthritis treated with bDMARDs or tsDMARDs are not at"/>
  <result pre="mortality from COVID-19. It is suggested that patients with chronic" exact="arthritis" post="treated with bDMARDs or tsDMARDs are not at increased"/>
  <result pre="with bDMARDs or tsDMARDs are not at increased risk of" exact="respiratory" post="or life-threatening complications from COVID-19 compared with the general"/>
  <result pre="reported in patients undergoing immunosuppression for organ transplantation, cancer, or" exact="autoimmune diseases." post="As we await more clinical studies and concrete data,"/>
  <result pre="same time, the clinicians should advocate against the discontinuation of" exact="chronic" post="immunosuppressive agents by patients. Such disruption of therapy could"/>
  <result pre="lead to an increased risk of relapses and morbidity from" exact="chronic" post="rheumatological conditions. Organ transplant patients and COVID-19 It is"/>
  <result pre="transplanted patients have reduced the severity of lung injury and" exact="atypical" post="symptoms of COVID-19. Although transplanted patients could be more"/>
  <result pre="COVID-19. Although transplanted patients could be more susceptible to COVID-19" exact="infection" post="with atypical manifestations, the chronic use of immunosuppressive drugs"/>
  <result pre="transplanted patients could be more susceptible to COVID-19 infection with" exact="atypical" post="manifestations, the chronic use of immunosuppressive drugs could potentially"/>
  <result pre="be more susceptible to COVID-19 infection with atypical manifestations, the" exact="chronic" post="use of immunosuppressive drugs could potentially represent a â€œprotective"/>
  <result pre="a â€œprotective factorâ€� for the severe clinical complication of the" exact="disease" post="through excessive cytokine reaction. However, there has been conflicting"/>
  <result pre="A small case study by Li et al described COVID-19" exact="infection" post="in two solid-organ transplanted patients with variable symptoms who"/>
  <result pre="of the immune system, especially T cells, leads to typical" exact="diffuse" post="alveolar injury in the lungs. Although immunosuppressed solid-organ transplanted"/>
  <result pre="solid-organ transplant (kidney, liver, and heart) recipients diagnosed with COVID-19." exact="Fever" post="(83.3%) and radiographic abnormalities in the form of unilateral"/>
  <result pre="COVID-19. Fever (83.3%) and radiographic abnormalities in the form of" exact="unilateral" post="or bilateral/multifocal consolidations (72.2%) were the most common presentations."/>
  <result pre="mortality in kidney transplant patients. The study identified 36 consecutive" exact="adult" post="kidney transplant recipients who tested positive for COVID-19. They"/>
  <result pre="recipients with COVID-19 had less fever as an initial symptom," exact="lower" post="cluster of differentiation 3 (CD3), CD4, and CD8 cell"/>
  <result pre="the usual 2-5% mortality in the general population. In this" exact="limited" post="cohort of kidney transplant patients, COVID-19 induced pneumonia is"/>
  <result pre="In this limited cohort of kidney transplant patients, COVID-19 induced" exact="pneumonia" post="is characterized by a high risk of progression and"/>
  <result pre="future will guide us with the management strategy of COVID-19" exact="infection" post="in solid-organ transplant patients and immunosuppression medications. Pregnancy and"/>
  <result pre="of COVID-19 infection in solid-organ transplant patients and immunosuppression medications." exact="Pregnancy" post="and COVID-19 The comprehensive impact of COVID-19 infection on"/>
  <result pre="immunosuppression medications. Pregnancy and COVID-19 The comprehensive impact of COVID-19" exact="infection" post="on a pregnant woman is currently unclear. International Federation"/>
  <result pre="complications during pregnancy and the potential effect on fetal and" exact="neonatal" post="outcomes. Hence, pregnant women require special attention concerning prevention,"/>
  <result pre="special attention concerning prevention, diagnosis, and management [77]. Comorbidities like" exact="hyperglycemia" post="and hypertension should be carefully managed with existing protocols"/>
  <result pre="concerning prevention, diagnosis, and management [77]. Comorbidities like hyperglycemia and" exact="hypertension" post="should be carefully managed with existing protocols as in"/>
  <result pre="carefully managed with existing protocols as in routine pregnancy. COVID-19" exact="infection" post="itself is not an indication for delivery unless maternal"/>
  <result pre="individualized, depending mainly on the clinical status of the patient," exact="gestational" post="age, and fetal condition. Currently, there is no evidence"/>
  <result pre="and fetal condition. Currently, there is no evidence that COVID-19" exact="infection" post="is associated with fetal or placental complications or risk"/>
  <result pre="is associated with fetal or placental complications or risk of" exact="congenital" post="malformation. The treatment approach depending on the severity of"/>
  <result pre="malformation. The treatment approach depending on the severity of COVID-19" exact="infection" post="is the same as for confirmed, suspected, and probable"/>
  <result pre="the support of a multidisciplinary team (obstetricians, intensivists, internists, neonatologists," exact="infectious disease" post="specialists). Currently, there is no proven antiviral treatment for"/>
  <result pre="support of a multidisciplinary team (obstetricians, intensivists, internists, neonatologists, infectious" exact="disease" post="specialists). Currently, there is no proven antiviral treatment for"/>
  <result pre="drugs are being investigated on patients with severe symptoms. A" exact="chest" post="CT scan may be included in the workup of"/>
  <result pre="the workup of pregnant women, if necessary, with suspected/probable/confirmed COVID-19" exact="infection" post="after discussing the risk and benefits with the patient."/>
  <result pre="at presentation were fever and cough. Two-thirds of patients had" exact="lymphopenia" post="and increased C-reactive protein (CRP), and 83% of cases"/>
  <result pre="increased C-reactive protein (CRP), and 83% of cases had a" exact="chest" post="CT scan showing multiple patches of ground (glass opacity"/>
  <result pre="COVID-19 suggested there was no evidence of vertical transmission in" exact="late pregnancy." post="There is currently insufficient evidence regarding the safety of"/>
  <result pre="the separation appears the best option, with attempts to express" exact="breast" post="milk to maintain milk production. If the patient is"/>
  <result pre="yet to be determined. COVID-19 related to maternal, fetal, and" exact="neonatal" post="outcomes will need further studies for more evidence-based management"/>
  <result pre="evidence-based management of pregnant women and neonates. COVID-19 in end-stage" exact="kidney disease" post="(ESKD) patients receiving chronic dialysis ESKD patients likely are"/>
  <result pre="management of pregnant women and neonates. COVID-19 in end-stage kidney" exact="disease" post="(ESKD) patients receiving chronic dialysis ESKD patients likely are"/>
  <result pre="and neonates. COVID-19 in end-stage kidney disease (ESKD) patients receiving" exact="chronic" post="dialysis ESKD patients likely are at significant risk of"/>
  <result pre="dialysis ESKD patients likely are at significant risk of COVID-19" exact="infection" post="due to suppression of the immune system, and may"/>
  <result pre="preventive measures are most critical to reduce the incidence of" exact="infection" post="in this vulnerable population. Strict protocols have been placed"/>
  <result pre="members have been particularly educated on guidelines to minimize the" exact="infection" post="risk and also to manage patients with signs of"/>
  <result pre="been implemented. Early recognition and isolation of individuals with a" exact="respiratory" post="infection, fever, cough, and upper airway involvement have been"/>
  <result pre="isolation of individuals with a respiratory infection, fever, cough, and" exact="upper" post="airway involvement have been critical. Aggressive disinfectant strategies and"/>
  <result pre="mask usage policies have been implemented. Patients with confirmed COVID-19" exact="infection" post="are admitted to cohort dialysis units if they are"/>
  <result pre="patients, including peritoneal dialysis (PD) patients, can also contract this" exact="viral infection" post="[82]. One case series from a HD center in"/>
  <result pre="including peritoneal dialysis (PD) patients, can also contract this viral" exact="infection" post="[82]. One case series from a HD center in"/>
  <result pre="case series from a HD center in Wuhan reported COVID-19" exact="infection" post="in 37 out of 230 HD patients (16.1%) and"/>
  <result pre="staff members (12.1%). Dialysis patients were noted to have lymphopenia," exact="lower" post="serum levels of inflammatory cytokines, and a milder clinical"/>
  <result pre="lower serum levels of inflammatory cytokines, and a milder clinical" exact="disease" post="than the other patients. Seven out of 33 COVID-19"/>
  <result pre="and it was presumed that the deaths were not directly" exact="secondary" post="to COVID-19, but due to cardiovascular and hyperkalemia. The"/>
  <result pre="deaths were not directly secondary to COVID-19, but due to" exact="cardiovascular" post="and hyperkalemia. The outcome of the four staff members"/>
  <result pre="intermittent RRT, conventional HD) to optimize the appropriate use of" exact="limited" post="dialysis resources [81]. The pandemic is still evolving, and"/>
  <result pre="some degree and are preparing for the next wave of" exact="infection" post="to impact in the fall and winter of 2020."/>
  <result pre="stay-at-home are worse than the medical catastrophe. However, in the" exact="absence of" post="widely available testing facilities, proven pharmacotherapeutics, and the introduction"/>
  <result pre="mainly used in combination with IFN for the treatment of" exact="hepatitis C" post="was tested in 86 patients for 14 days for"/>
  <result pre="in the active intervention group, and the control group had" exact="viral" post="clearance at an average of 7 days and 12"/>
  <result pre="COVID-19, as per the above, they could be manufactured at" exact="lower" post="costs [87]. The authors of this article have decided"/>
  <result pre="into the following broad categories: Slowing down the transmission of" exact="disease" post="and providing care for severely sick ones This is"/>
  <result pre="sick ones This is to ensure the appropriate utilization of" exact="limited" post="healthcare resources and to avoid overwhelming the global healthcare"/>
  <result pre="avoid overwhelming the global healthcare infrastructures. Ramping up testing for" exact="infection" post="and antibody testing to assess the level of viral"/>
  <result pre="for infection and antibody testing to assess the level of" exact="viral" post="prevalence and immunity So, resources can be allocated to"/>
  <result pre="screen the patients and surgical team preoperative to ascertain their" exact="infection" post="status and go ahead with even routine surgical procedures,"/>
  <result pre="proposals have been put forth by organizations such as the" exact="American" post="Enterprise Institute, the Center for American Progress, and Harvard"/>
  <result pre="organizations such as the American Enterprise Institute, the Center for" exact="American" post="Progress, and Harvard Universityâ€™s Edmond J. Safra Center for"/>
  <result pre="summarized as follows. The first step is to keep the" exact="infection" post="rates low by imposing strict social distancing measures. Meanwhile,"/>
  <result pre="restrictions, anyone who needs a test can be tested for" exact="infection" post="as well as antibodies that would identify who are"/>
  <result pre="lives, health and wellbeing. Supplementary Material Suppl 1 Summary of" exact="Multiple" post="Clinical Trials Available All Over the World on COVID-19."/>
  <result pre="article. VM is responsible for creating the supplementary table and" exact="complete" post="review of the manuscript. All the authors reviewed the"/>
  <result pre="WHO World Health Organization 2019-nCoV 2019 novel coronavirus COVID-19 coronavirus" exact="disease" post="2019 SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 FDA"/>
  <result pre="2019-nCoV 2019 novel coronavirus COVID-19 coronavirus disease 2019 SARS-CoV-2 severe" exact="acute" post="respiratory syndrome coronavirus 2 FDA Food and Drug Administration"/>
  <result pre="2019 novel coronavirus COVID-19 coronavirus disease 2019 SARS-CoV-2 severe acute" exact="respiratory" post="syndrome coronavirus 2 FDA Food and Drug Administration MERS"/>
  <result pre="novel coronavirus COVID-19 coronavirus disease 2019 SARS-CoV-2 severe acute respiratory" exact="syndrome" post="coronavirus 2 FDA Food and Drug Administration MERS Middle"/>
  <result pre="coronavirus 2 FDA Food and Drug Administration MERS Middle Eastern" exact="respiratory" post="syndrome AKI acute kidney injury ESKD end-stage kidney disease"/>
  <result pre="2 FDA Food and Drug Administration MERS Middle Eastern respiratory" exact="syndrome" post="AKI acute kidney injury ESKD end-stage kidney disease ACEI"/>
  <result pre="Food and Drug Administration MERS Middle Eastern respiratory syndrome AKI" exact="acute" post="kidney injury ESKD end-stage kidney disease ACEI angiotensin-converting enzyme"/>
  <result pre="and Drug Administration MERS Middle Eastern respiratory syndrome AKI acute" exact="kidney injury" post="ESKD end-stage kidney disease ACEI angiotensin-converting enzyme inhibitor RNA"/>
  <result pre="Middle Eastern respiratory syndrome AKI acute kidney injury ESKD end-stage" exact="kidney disease" post="ACEI angiotensin-converting enzyme inhibitor RNA ribonucleic acid ICU intensive"/>
  <result pre="Eastern respiratory syndrome AKI acute kidney injury ESKD end-stage kidney" exact="disease" post="ACEI angiotensin-converting enzyme inhibitor RNA ribonucleic acid ICU intensive"/>
  <result pre="enzyme inhibitor RNA ribonucleic acid ICU intensive care unit ARDS" exact="acute" post="respiratory distress syndrome CT computed tomography ECMO extracorporeal membrane"/>
  <result pre="inhibitor RNA ribonucleic acid ICU intensive care unit ARDS acute" exact="respiratory" post="distress syndrome CT computed tomography ECMO extracorporeal membrane oxygenation"/>
  <result pre="ribonucleic acid ICU intensive care unit ARDS acute respiratory distress" exact="syndrome" post="CT computed tomography ECMO extracorporeal membrane oxygenation CDC Centers"/>
  <result pre="CT computed tomography ECMO extracorporeal membrane oxygenation CDC Centers for" exact="Disease" post="Control and Prevention PPE personal protective equipment NSAIDS non-steroidal"/>
  <result pre="powered air-purifying respirator CP convalescent plasma VQ ventilation-perfusion HIV human" exact="immunodeficiency" post="virus References References 1Centers for Disease Control and Prevention."/>
  <result pre="VQ ventilation-perfusion HIV human immunodeficiency virus References References 1Centers for" exact="Disease" post="Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html. Accessed on June 1, 2020"/>
  <result pre="treatment for 2019-nCoV lung injuryLancet20203951022347347510.1016/S0140-6736(20)30317-232043983 6WuCChenXCaiYXiaJZhouXXuSHuangHet al.Risk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients with coronavirus"/>
  <result pre="for 2019-nCoV lung injuryLancet20203951022347347510.1016/S0140-6736(20)30317-232043983 6WuCChenXCaiYXiaJZhouXXuSHuangHet al.Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
  <result pre="lung injuryLancet20203951022347347510.1016/S0140-6736(20)30317-232043983 6WuCChenXCaiYXiaJZhouXXuSHuangHet al.Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
  <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in Wuhan, ChinaJAMA Intern Med202010.1001/jamainternmed.2020.0994 7TangNLiDWangXSunZAbnormal coagulation"/>
  <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan, ChinaJAMA Intern Med202010.1001/jamainternmed.2020.0994 7TangNLiDWangXSunZAbnormal coagulation parameters are"/>
  <result pre="Haemost202018484484710.1111/jth.1476832073213 8ZhouFYuTDuRFanGLiuYLiuZXiangJet al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="COVID-19 in Wuhan, China: a retrospective cohort studyLancet2020395102291054106210.1016/S0140-6736(20)30566-332171076 9Centers for" exact="Disease" post="Control and Prevention. People who are at higher risk"/>
  <result pre="illness https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html. Accessed on April 1, 2020 10Statement from the" exact="American" post="Heart Association, the Heart Failure Society of America and"/>
  <result pre="https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html. Accessed on April 1, 2020 10Statement from the American" exact="Heart" post="Association, the Heart Failure Society of America and the"/>
  <result pre="April 1, 2020 10Statement from the American Heart Association, the" exact="Heart Failure" post="Society of America and the American College of Cardiology."/>
  <result pre="1, 2020 10Statement from the American Heart Association, the Heart" exact="Failure" post="Society of America and the American College of Cardiology."/>
  <result pre="Heart Association, the Heart Failure Society of America and the" exact="American" post="College of Cardiology. Patients taking ACE-i and ARBs who"/>
  <result pre="https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician 11YuanSStatins may decrease the fatality rate of middle east" exact="respiratory" post="syndrome infectionmBio20156e0112010.1128/mBio.01120-1526265720 12The American Academy of Dermatology. https://assets.ctfassets.net/1ny4yoiyrqia/PicgNuD0IpYd9MSOwab47/023ce3cf6eb82cb304b4ad4a8ef50d56/Biologics_and_COVID-19.pdf 13GuanWJNiZYHuYLiangWHOuCQHeJXLiuLet"/>
  <result pre="11YuanSStatins may decrease the fatality rate of middle east respiratory" exact="syndrome" post="infectionmBio20156e0112010.1128/mBio.01120-1526265720 12The American Academy of Dermatology. https://assets.ctfassets.net/1ny4yoiyrqia/PicgNuD0IpYd9MSOwab47/023ce3cf6eb82cb304b4ad4a8ef50d56/Biologics_and_COVID-19.pdf 13GuanWJNiZYHuYLiangWHOuCQHeJXLiuLet al.Clinical"/>
  <result pre="the fatality rate of middle east respiratory syndrome infectionmBio20156e0112010.1128/mBio.01120-1526265720 12The" exact="American" post="Academy of Dermatology. https://assets.ctfassets.net/1ny4yoiyrqia/PicgNuD0IpYd9MSOwab47/023ce3cf6eb82cb304b4ad4a8ef50d56/Biologics_and_COVID-19.pdf 13GuanWJNiZYHuYLiangWHOuCQHeJXLiuLet al.Clinical characteristics of coronavirus"/>
  <result pre="American Academy of Dermatology. https://assets.ctfassets.net/1ny4yoiyrqia/PicgNuD0IpYd9MSOwab47/023ce3cf6eb82cb304b4ad4a8ef50d56/Biologics_and_COVID-19.pdf 13GuanWJNiZYHuYLiangWHOuCQHeJXLiuLet al.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J Med2020382181708172010.1056/NEJMoa200203232109013 14Centers for Disease"/>
  <result pre="coronavirus disease 2019 in ChinaN Engl J Med2020382181708172010.1056/NEJMoa200203232109013 14Centers for" exact="Disease" post="Control and Prevention. Interim clinical guidance for management of"/>
  <result pre="guidelines on the management of critically ill adults with Coronavirus" exact="Disease" post="2019 (COVID-19)Intensive Care Med202046585488710.1007/s00134-020-06022-532222812 16GattinoniLChiumelloDCaironiPBusanaMRomittiFBrazziLCamporotaLCOVID-19 pneumonia: different respiratory treatments"/>
  <result pre="with Coronavirus Disease 2019 (COVID-19)Intensive Care Med202046585488710.1007/s00134-020-06022-532222812 16GattinoniLChiumelloDCaironiPBusanaMRomittiFBrazziLCamporotaLCOVID-19 pneumonia: different" exact="respiratory" post="treatments for different phenotypes?Intensive Care Med202010.1007/s00134-020-06033-2 17MariniJJGattinoniLManagement of COVID-19"/>
  <result pre="respiratory treatments for different phenotypes?Intensive Care Med202010.1007/s00134-020-06033-2 17MariniJJGattinoniLManagement of COVID-19" exact="Respiratory" post="DistressJAMA202010.1001/jama.2020.682532329799 18LuksAMFreerLGrissomCKMcIntoshSESchoeneRBSwensonERHackettPHCOVID-19 lung injury is not high altitude pulmonary"/>
  <result pre="COVID-19 Respiratory DistressJAMA202010.1001/jama.2020.682532329799 18LuksAMFreerLGrissomCKMcIntoshSESchoeneRBSwensonERHackettPHCOVID-19 lung injury is not high altitude" exact="pulmonary" post="edemaHigh Alt Med Biol202010.1089/ham.2020.005532281877 19TranKCimonKSevernMPessoa-SilvaCLConlyJAerosol generating procedures and risk"/>
  <result pre="Med Biol202010.1089/ham.2020.005532281877 19TranKCimonKSevernMPessoa-SilvaCLConlyJAerosol generating procedures and risk of transmission of" exact="acute" post="respiratory infections to healthcare workers: a systematic reviewPLoS One201274e3579710.1371/journal.pone.003579722563403"/>
  <result pre="Biol202010.1089/ham.2020.005532281877 19TranKCimonKSevernMPessoa-SilvaCLConlyJAerosol generating procedures and risk of transmission of acute" exact="respiratory" post="infections to healthcare workers: a systematic reviewPLoS One201274e3579710.1371/journal.pone.003579722563403 20PanCChenLLuCZhangWXiaJASklarMCDuBet"/>
  <result pre="19TranKCimonKSevernMPessoa-SilvaCLConlyJAerosol generating procedures and risk of transmission of acute respiratory" exact="infections" post="to healthcare workers: a systematic reviewPLoS One201274e3579710.1371/journal.pone.003579722563403 20PanCChenLLuCZhangWXiaJASklarMCDuBet al.Lung"/>
  <result pre="workers: a systematic reviewPLoS One201274e3579710.1371/journal.pone.003579722563403 20PanCChenLLuCZhangWXiaJASklarMCDuBet al.Lung Recruitability in COVID-19-associated" exact="Acute" post="Respiratory Distress Syndrome: A Single-Center Observational StudyAm J Respir"/>
  <result pre="a systematic reviewPLoS One201274e3579710.1371/journal.pone.003579722563403 20PanCChenLLuCZhangWXiaJASklarMCDuBet al.Lung Recruitability in COVID-19-associated Acute" exact="Respiratory" post="Distress Syndrome: A Single-Center Observational StudyAm J Respir Crit"/>
  <result pre="Crit Care Med2020201101294129710.1164/rccm.202003-0527LE32200645 21HenryBMLippiGPoor survival with extracorporeal membrane oxygenation in" exact="acute" post="respiratory distress syndrome (ARDS) due to coronavirus disease 2019"/>
  <result pre="Care Med2020201101294129710.1164/rccm.202003-0527LE32200645 21HenryBMLippiGPoor survival with extracorporeal membrane oxygenation in acute" exact="respiratory" post="distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19):"/>
  <result pre="21HenryBMLippiGPoor survival with extracorporeal membrane oxygenation in acute respiratory distress" exact="syndrome" post="(ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis"/>
  <result pre="oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus" exact="disease" post="2019 (COVID-19): Pooled analysis of early reportsJ Crit Care202058272810.1016/j.jcrc.2020.03.01132279018"/>
  <result pre="analysis of early reportsJ Crit Care202058272810.1016/j.jcrc.2020.03.01132279018 22AsadaMYoshidaMSuzukiTHatachiYSasakiTYasudaHNakayamaKet al.Macrolide antibiotics inhibit" exact="respiratory" post="syncytial virus infection in human airway epithelial cellsAntiviral Res200983219120010.1016/j.antiviral.2009.05.00319463856"/>
  <result pre="early reportsJ Crit Care202058272810.1016/j.jcrc.2020.03.01132279018 22AsadaMYoshidaMSuzukiTHatachiYSasakiTYasudaHNakayamaKet al.Macrolide antibiotics inhibit respiratory syncytial" exact="virus infection" post="in human airway epithelial cellsAntiviral Res200983219120010.1016/j.antiviral.2009.05.00319463856 23RetallackHDi LulloEAriasCKnoppKALaurieMTSandoval-EspinosaCMancia LeonWRet"/>
  <result pre="reportsJ Crit Care202058272810.1016/j.jcrc.2020.03.01132279018 22AsadaMYoshidaMSuzukiTHatachiYSasakiTYasudaHNakayamaKet al.Macrolide antibiotics inhibit respiratory syncytial virus" exact="infection" post="in human airway epithelial cellsAntiviral Res200983219120010.1016/j.antiviral.2009.05.00319463856 23RetallackHDi LulloEAriasCKnoppKALaurieMTSandoval-EspinosaCMancia LeonWRet"/>
  <result pre="al.Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway" exact="epithelial" post="cellsAntiviral Res200983219120010.1016/j.antiviral.2009.05.00319463856 23RetallackHDi LulloEAriasCKnoppKALaurieMTSandoval-EspinosaCMancia LeonWRet al.Zika virus cell tropism"/>
  <result pre="LulloEAriasCKnoppKALaurieMTSandoval-EspinosaCMancia LeonWRet al.Zika virus cell tropism in the developing human" exact="brain" post="and inhibition by azithromycinProc Natl Acad Sci U S"/>
  <result pre="of an open-label non-randomized clinical trialInt J Antimicrob Agents202010594910.1016/j.ijantimicag.2020.10594932205204 26SimpsonTFKovacsRJStecklerECVentricular" exact="arrhythmia" post="risk due to hydroxychloroquine-azithromycin treatment for COVID-19Cardiology2020 27MagagnoliJNarendranSPereiraFCummingsTHardinJWSuttonSSAmbatiJOutcomes of"/>
  <result pre="Covid-19medRxiv202010.1101/2020.04.16.20065920 28Food and Drug Administration. https://www.fda.gov/media/137564/download 29SandersJMMonogueMLJodlowskiTZCutrellJBPharmacologic treatments for coronavirus" exact="disease" post="2019 (COVID-19): A ReviewJAMA202010.1001/jama.2020.6019 30TanakaTNarazakiMKishimotoTImmunotherapeutic implications of IL-6 blockade"/>
  <result pre="FDA-approved compound library identifies four small-molecule inhibitors of Middle East" exact="respiratory" post="syndrome coronavirus replication in cell cultureAntimicrob Agents Chemother20145884875488410.1128/AAC.03011-1424841269 33CaoBWangYWenDLiuWWangJFanGRuanLet"/>
  <result pre="compound library identifies four small-molecule inhibitors of Middle East respiratory" exact="syndrome" post="coronavirus replication in cell cultureAntimicrob Agents Chemother20145884875488410.1128/AAC.03011-1424841269 33CaoBWangYWenDLiuWWangJFanGRuanLet al.A"/>
  <result pre="Chemother20145884875488410.1128/AAC.03011-1424841269 33CaoBWangYWenDLiuWWangJFanGRuanLet al.A Trial of Lopinavir-Ritonavir in Adults Hospitalized with" exact="Severe" post="Covid-19N Engl J Med2020382191787179910.1056/NEJMoa200128232187464 34HurstMFauldsDLopinavirDrugs20006061380138110.2165/00003495-200060060-0000911152017 35CarlosDSpillerFSoutoFOTrevelinSCBorgesVFde FreitasAAlves-FilhoJCet al.Histamine h2"/>
  <result pre="signaling in the pathogenesis of sepsis: studies in a murine" exact="diabetes" post="modelJ Immunol201319131373138210.4049/jimmunol.120290723817413 36CizMLojekAModulation of neutrophil oxidative burst via histamine"/>
  <result pre="of immune-related diseasesInt Immunopharmacol20197015616610.1016/j.intimp.2019.02.02630802678 38Kapinska-MrowieckaMTurowskiG[Efficacy of cimetidine in treatment of" exact="Herpes zoster" post="in the first 5 days from the moment of"/>
  <result pre="immune-related diseasesInt Immunopharmacol20197015616610.1016/j.intimp.2019.02.02630802678 38Kapinska-MrowieckaMTurowskiG[Efficacy of cimetidine in treatment of Herpes" exact="zoster" post="in the first 5 days from the moment of"/>
  <result pre="zoster in the first 5 days from the moment of" exact="disease" post="manifestation]Pol Tyg Lek19965123-263383399273526 39KurzrockRAuberMMavligitGMCimetidine therapy of herpes simplex virus"/>
  <result pre="the moment of disease manifestation]Pol Tyg Lek19965123-263383399273526 39KurzrockRAuberMMavligitGMCimetidine therapy of" exact="herpes" post="simplex virus infections in immunocompromised patientsClin Exp Dermatol198712532633110.1111/j.1365-2230.1987.tb02501.x3446417 40HarcourtJPWorleyGLeightonSECimetidine"/>
  <result pre="disease manifestation]Pol Tyg Lek19965123-263383399273526 39KurzrockRAuberMMavligitGMCimetidine therapy of herpes simplex virus" exact="infections" post="in immunocompromised patientsClin Exp Dermatol198712532633110.1111/j.1365-2230.1987.tb02501.x3446417 40HarcourtJPWorleyGLeightonSECimetidine treatment for recurrent"/>
  <result pre="virus infections in immunocompromised patientsClin Exp Dermatol198712532633110.1111/j.1365-2230.1987.tb02501.x3446417 40HarcourtJPWorleyGLeightonSECimetidine treatment for" exact="recurrent" post="respiratory papillomatosisInt J Pediatr Otorhinolaryngol199951210911310.1016/S0165-5876(99)00279-710619624 41ZhangWWangJSuBLiRDingZKangYWangBCimetidine augments Th1/Th2 dual"/>
  <result pre="infections in immunocompromised patientsClin Exp Dermatol198712532633110.1111/j.1365-2230.1987.tb02501.x3446417 40HarcourtJPWorleyGLeightonSECimetidine treatment for recurrent" exact="respiratory" post="papillomatosisInt J Pediatr Otorhinolaryngol199951210911310.1016/S0165-5876(99)00279-710619624 41ZhangWWangJSuBLiRDingZKangYWangBCimetidine augments Th1/Th2 dual polarized"/>
  <result pre="immune responses to recombinant HBV antigensVaccine20112929-304862486810.1016/j.vaccine.2011.03.09121481324 42BourinbaiarASFruhstorferECThe effect of histamine" exact="type 2" post="receptor antagonists on human immunodeficiency virus (HIV) replication: identification"/>
  <result pre="42BourinbaiarASFruhstorferECThe effect of histamine type 2 receptor antagonists on human" exact="immunodeficiency" post="virus (HIV) replication: identification of a new class of"/>
  <result pre="of a new class of antiviral agentsLife Sci19965923PL365PL37010.1016/S0024-3205(96)00553-X 43LiuYJIPC: professional" exact="type 1" post="interferon-producing cells and plasmacytoid dendritic cell precursorsAnnu Rev Immunol20052327530610.1146/annurev.immunol.23.021704.11563315771572"/>
  <result pre="44ChanJFYaoYYeungMLDengWBaoLJiaLLiFet al.Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ Infect"/>
  <result pre="al.IFN-I response timing relative to virus replication determines MERS coronavirus" exact="infection" post="outcomesJ Clin Invest20191303625363910.1172/JCI12636331355779 47LukeTCKilbaneEMJacksonJLHoffmanSLMeta-analysis: convalescent blood products for Spanish"/>
  <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
  <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
  <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysisJ"/>
  <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysisJ Infect Dis20152111809010.1093/infdis/jiu39625030060"/>
  <result pre="A202011720109701097510.1073/pnas.200561511732350134 60ChangJCSepsis and septic shock: endothelial molecular pathogenesis associated with" exact="vascular" post="microthrombotic diseaseThromb J2019171010.1186/s12959-019-0198-431160889 61HouPCFilbinMRWangHNgoLHuangDTAirdWCYealyDMet al.Endothelial permeability and hemostasis in"/>
  <result pre="results from the ProCESS trialChest20171521223110.1016/j.chest.2017.01.01028109962 62JohanssonPIStensballeJOstrowskiSRShock induced endotheliopathy (SHINE) in" exact="acute" post="critical illness - a unifying pathophysiologic mechanismCrit Care20172112510.1186/s13054-017-1605-528179016 63NguyenTCCarcilloJABench-to-bedside"/>
  <result pre="63NguyenTCCarcilloJABench-to-bedside review: thrombocytopenia-associated multiple organ failure - a newly appreciated" exact="syndrome" post="in the critically illCrit Care200610623510.1186/cc506417096864 64BusundRKouklineVUtrobinUNedashkovskyEPlasmapheresis in severe sepsis"/>
  <result pre="MERS or COVID-19: initial assessmentJ Int AIDS Soc2020234e2548910.1002/jia2.2548932293807 69AuKReedGCurtisJRKremerJMGreenbergJDStrandVFurstDEet al.High" exact="disease" post="activity is associated with an increased risk of infection"/>
  <result pre="al.High disease activity is associated with an increased risk of" exact="infection" post="in patients with rheumatoid arthritisAnn Rheum Dis201170578579110.1136/ard.2010.12863721288960 70MontiSBalduzziSDelvinoPBellisEQuadrelliVSMontecuccoCClinical course"/>
  <result pre="70MontiSBalduzziSDelvinoPBellisEQuadrelliVSMontecuccoCClinical course of COVID-19 in a series of patients with" exact="chronic" post="arthritis treated with immunosuppressive targeted therapiesAnn Rheum Dis202079566766810.1136/annrheumdis-2020-21742432241793 71VeneritoVLopalcoGIannoneFCOVID-19,"/>
  <result pre="course of COVID-19 in a series of patients with chronic" exact="arthritis" post="treated with immunosuppressive targeted therapiesAnn Rheum Dis202079566766810.1136/annrheumdis-2020-21742432241793 71VeneritoVLopalcoGIannoneFCOVID-19, rheumatic"/>
  <result pre="chronic arthritis treated with immunosuppressive targeted therapiesAnn Rheum Dis202079566766810.1136/annrheumdis-2020-21742432241793 71VeneritoVLopalcoGIannoneFCOVID-19," exact="rheumatic" post="diseases and immunosuppressive drugs: an appeal for medication adherenceRheumatol"/>
  <result pre="appeal for medication adherenceRheumatol Int202040582782810.1007/s00296-020-04566-932232551 72LiFCaiJDongNFirst cases of COVID-19 in" exact="heart" post="transplantation from ChinaJ Heart Lung Transplant202039549649710.1016/j.healun.2020.03.00632362394 73RomanelliAMascoloSImmunosuppression drug-related and"/>
  <result pre="Int202040582782810.1007/s00296-020-04566-932232551 72LiFCaiJDongNFirst cases of COVID-19 in heart transplantation from ChinaJ" exact="Heart" post="Lung Transplant202039549649710.1016/j.healun.2020.03.00632362394 73RomanelliAMascoloSImmunosuppression drug-related and clinical manifestation of Coronavirus"/>
  <result pre="Heart Lung Transplant202039549649710.1016/j.healun.2020.03.00632362394 73RomanelliAMascoloSImmunosuppression drug-related and clinical manifestation of Coronavirus" exact="disease" post="2019: A therapeutical hypothesisAm J Transplant202010.1111/ajt.1590532243698 74Fernandez-RuizMAndresALoinazCDelgadoJFLopez-MedranoFSan JuanRGonzalezEet al.COVID-19"/>
  <result pre="Gynecology and Obstetrics). https://www.figo.org/news/figo-covid-19-resource-s 77PoonLCYangHKapurAMelamedNDaoBDivakarHMcIntyreHDet al.Global interim guidance on coronavirus" exact="disease" post="2019 (COVID-19) during pregnancy and puerperium from FIGO and"/>
  <result pre="78ChenHGuoJWangCLuoFYuXZhangWLiJet al.Clinical characteristics and intrauterine vertical transmission potential of COVID-19" exact="infection" post="in nine pregnant women: a retrospective review of medical"/>
  <result pre="SARS-CoV-2 (COVID-19) pandemic in haemodialysis centresNephrol Dial Transplant202035573774110.1093/ndt/gfaa06932196116 81AdapaSAeddulaNRKonalaVMChennaANaramalaSMadhiraBRGayamVBallaMMuppidiVBoseSCOVID-19 associated" exact="renal failure" post="and challenges to deliver optimal renal replacement therapy in"/>
  <result pre="Med Res2020[Article in Press] 82BoseSAdapaSKonalaVMGopalRHSohailSNaramalaSKondakindiHet al.Atypical presentation of novel coronavirus" exact="disease" post="19 in a peritoneal dialysis patientJ Investig Med High"/>
  <result pre="High Impact Case Rep2020[Article in Press] 83MaYDiaoBLvXet al.2019 Novel coronavirus" exact="disease" post="in hemodialysis (HD) patients: report from one HD Center"/>
  <result pre="88World Health Organization. https://www.who.int/docs/default-source/coronaviruse/covid-strategy-update-14april2020.pdf?sfvrsn=29da3ba0_6 89National coronavirus response. https://www.aei.org/wp-content/uploads/2020/03/National-Coronavirus-Response-a-Road-Map-to-Recovering-2.pdf 90Center for" exact="American" post="Progress. https://www.americanprogress.org/issues/healthcare/news/2020/04/03/482613/national-state-plan-end-coronavirus-crisis/"/>
 </snippets>
</snippetsTree>
